Abstract
The present study was conducted to develop and evaluate an experimental ISCOM-based infectious bursal disease (IBD) vaccine. The indigenous very virulent infectious bursal disease virus (vvIBDV) already attenuated and adapted to Vero cell line was used. After denaturation of viral proteins with sodium dodecyl sulphate (SDS), an IBD-ISCOM was constructed. The non-incorporated viral components were separated from ISCOM by centrifugation of dialysate. The pathogenicity and immunogenicity trials were conducted in 3-week-old broiler chicken. A commercial oil-emulsified vaccine (CEVAC IBD K) was used for comparison. There were no clinical signs of disease, gross or microscopic lesions in bursa of Fabricius in group G1 vaccinated with ISCOM-based vaccine and bursa to body weight ratio were comparable to un-vaccinated control group (G3). The virus-neutralizing antibody titers were significantly (P<0.05) higher in group G1 as compared with group G2 which was vaccinated with commercial vaccine. On challenge with vvIBDV, 100%, 75% and 0.00% protection was achieved in G1, G2 and G3, respectively. The results indicated that ISCOM-based IBD vaccine is safe and immunogenic.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
